{
    "clinical_study": {
        "@rank": "43352", 
        "arm_group": {
            "arm_group_label": "Group ACYW135 Meningococcal Polysaccharide Vaccine", 
            "arm_group_type": "Experimental", 
            "description": "0.5ml/ vial"
        }, 
        "brief_summary": {
            "textblock": "The clinical trial was designed to evaluate the safety against Group ACYW135 Meningococcal\n      Polysaccharide Vaccine of Hualan administered on subjects 2 years of age and older."
        }, 
        "brief_title": "Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 001", 
        "completion_date": {
            "#text": "May 2006", 
            "@type": "Actual"
        }, 
        "condition": "Meningitis", 
        "condition_browse": {
            "mesh_term": "Meningitis"
        }, 
        "detailed_description": {
            "textblock": "Complying with requirements of the approval letter of clinical trial issued by SFDA\n      (Approval Letter No.: 2006L01017), Hualan conducted phase I clinical trial of Group ACYW135\n      Meningococcal Polysaccharide Vaccine. The safety end points were the presence of any\n      systemic, local and adverse reaction."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy permanent residence 2 years of age and older, the subjects (or their\n             guardians) are able to understand and sign the informed consent;\n\n          -  Healthy male or female by oral history, physical examination and clinical judgment\n             and who complies with vaccination of this product;\n\n          -  Be able to comply with the requirements of clinical trial protocol and immunogenicity\n             examination;\n\n          -  Have no history of vaccination within the past 3 months and vaccination with other\n             products within the last 2 weeks;\n\n          -  Axillary temperature \u226437.0\u2103.\n\n        Exclusion Criteria:\n\n          -  Any acute disease, such as: tumor, autoimmunity disease, progressive atherosclerotic\n             disease or diabetes with complication, chronic obstructive pulmonary disease need\n             oxygen uptake, acute or progressive hepatopathy or nephropathy, congestive\n             heart-failure, etc.;\n\n          -  Allergic to vaccines or drugs (history of allergy to any vaccine in the past);\n\n          -  History of neurologic symptom or signs;\n\n          -  Known or suspected (or high risk) impaired or abnormal immune function, e.g.: receive\n             immunosuppressant or immunopotentiator therapy, take immunoglobulin or blood product\n             or plasma extract (except the gastrointestinal tract) within the past 3 months, HIV\n             infection or related disease, etc.;\n\n          -  History of meningitis infection or vaccination of meningococcal vaccine within the\n             past 3 months;\n\n          -  History of receiving other vaccines or immunoglobulin injection or any research\n             drugs;\n\n          -  Any acute disease needing application of antibiotics or anti-virus treatment in the\n             whole body within the past 1 week;\n\n          -  History of fever within the past 3 days (axillary temperature \u226538.0\u2103);\n\n          -  Participating in another clinical trial;\n\n          -  History of allergy, eclampsia, epilepsy, encephalopathy and mental disease or family\n             disease;\n\n          -  Thrombopenia or other coagulopathy that may cause contraindication to intramuscular\n             injection;\n\n          -  Acute chronic disease (such as Down syndrome, diabetes, sickle cell anemia or\n             neurologic disease, Guillain-Barre Syndrome);\n\n          -  Known or suspected diseases, including: respiratory system disease, acute infection\n             or active stage of chronic disease, SBAV infection of children or mothers,\n             cardiovascular disease, acute hypertension, cancer treatment, skin disease, etc.;\n\n          -  Pregnancy;\n\n          -  Any condition that, in the judgment of investigator, may affect trial assessment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661725", 
            "org_study_id": "Hualanbio-Meningococcal CT 001", 
            "secondary_id": "Hualanbio-phase I CT"
        }, 
        "intervention": {
            "arm_group_label": "Group ACYW135 Meningococcal Polysaccharide Vaccine", 
            "description": "60 subjects were divided into three groups (20 subjects each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime", 
            "intervention_name": "Group ACYW135 Meningococcal Polysaccharide Vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Hualan Bio"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Group ACYW135 Meningococcal Polysaccharide Vaccine", 
        "lastchanged_date": "August 6, 2012", 
        "number_of_arms": "1", 
        "official_title": "Phase I Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine", 
        "overall_official": {
            "affiliation": "Immunization Program Institute of Jiangsu Provincial Center for Disease Control and Prevention", 
            "last_name": "Fubao Ma, Bachelor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "All systemic and local adverse reactions and related adverse events on day 28 after the vaccination", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Day 28 after vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661725"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hualan Biological Engineering, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hualan Biological Engineering, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2006", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}